Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.3
2.4
Journals
Medicina
Special Issues
Immune-Mediated Skin Diseases: Future Therapeutic Perspectives
share announcement

Immune-Mediated Skin Diseases: Future Therapeutic Perspectives

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Dermatology".

Deadline for manuscript submissions: closed (28 February 2023) | Viewed by 26248

Special Issue Editor

Prof. Dr. Mauro Salvatore Alessandro Alaibac

E-Mail Website
Guest Editor
Department of Dermatology, University of Padua, Padova, Italy
Interests: cutaneous oncology; immunodermatology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Immuno-mediated skin diseases are a common and clinically heterogeneous group of cutaneous conditions. In recent years, there has been a significant increase in the understanding of the pathogenesis of these diseases which are often difficult to treat. The therapeutic approaches for immune-mediated skin diseases have been transformed in the past two decades. We have moved from the utilization of broad-spectrum immune modulators to the use of agents with high specificity, arising from monoclonal and molecular biotechnology and, more recently, highly targeted small molecule synthesis.

This Special Issue will focus on recent immunotherapy approaches and novel targeted therapy using bioactive small molecules for the treatment of immune-mediated skin diseases. Submissions of new research papers, reviews, commentaries and case reports are welcome to this Special Issue.

Prof. Dr. Mauro Salvatore Alessandro Alaibac
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • immuno-mediated skin diseases
  • immunotherapy
  • small molecules
  • dermatology
  • dermatoses

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (7 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Editorial

Jump to: Research, Other

4 pages, 226 KiB  
Editorial
Immune-Mediated Skin Diseases: Future Therapeutic Perspectives
by Mauro Alaibac
Medicina 2023, 59(10), 1787; https://doi.org/10.3390/medicina59101787 - 8 Oct 2023
Viewed by 1159
Abstract
Immuno-mediated skin diseases are a common and clinically heterogeneous group of cutaneous conditions [...] Full article
(This article belongs to the Special Issue Immune-Mediated Skin Diseases: Future Therapeutic Perspectives)

Research

Jump to: Editorial, Other

10 pages, 1173 KiB  
Article
Effect of Dupilumab on Sexual Desire in Adult Patients with Moderate to Severe Atopic Dermatitis
by Maddalena Napolitano, Gabriella Fabbrocini, Sara Kastl, Teresa Battista, Adriana Di Guida, Fabrizio Martora, Vincenzo Picone, Virginia Ventura and Cataldo Patruno
Medicina 2022, 58(12), 1708; https://doi.org/10.3390/medicina58121708 - 23 Nov 2022
Cited by 2 | Viewed by 2915
Abstract
Background: Atopic dermatitis (AD) is a chronic inflammatory condition causing itching skin, with a significant psychosocial impact on patients and relatives. AD affects 15 to 30% of children and 2 to 10% of adults. AD significantly affects patients’ quality of life (QoL) [...] Read more.
Background: Atopic dermatitis (AD) is a chronic inflammatory condition causing itching skin, with a significant psychosocial impact on patients and relatives. AD affects 15 to 30% of children and 2 to 10% of adults. AD significantly affects patients’ quality of life (QoL) given the chronicity and symptoms of the disease. Most AD patients have reported that the disease affects daily life, resulting in limited social contact and a strong impact on sexual health (SH), especially in moderate–severe cases. Materials and methods: We performed a prospective study from 1 May 2020 to 1 May 2022; the aim of the study was to evaluate the impact of moderate to severe AD on sexual desire, seduction, and partner relationships, and describe how it varies following dupilumab therapy. We used the Sexual Desire Inventory-2 (SDI-2), a validated instrument consisting of 14 items; moreover, we used a second questionnaire with eight items, an unvalidated instrument created specifically for this study, to obtain the assessment of the influence of AD on the body image, sexuality, and self-perception of those affected. Results and Conclusions: The impact of AD on sexual desire assessed using SDI-2 showed a significant improvement in both sexes during dupilumab treatment from the baseline to W4 and W16. Similar results were obtained with our questionnaire. Full article
(This article belongs to the Special Issue Immune-Mediated Skin Diseases: Future Therapeutic Perspectives)
►▼ Show Figures

Figure 1

Other

Jump to: Editorial, Research

7 pages, 969 KiB  
Case Report
Atopic Dermatitis and Ulcerative Colitis Successfully Treated with Upadacitinib
by Teresa Grieco, Martina Caviglia, Giuseppina Cusano, Alvise Sernicola, Camilla Chello, Ester Del Duca, Carmen Cantisani, Alberto Taliano, Nicolò Sini, Gianluca Ianiro and Giovanni Pellacani
Medicina 2023, 59(3), 542; https://doi.org/10.3390/medicina59030542 - 10 Mar 2023
Cited by 6 | Viewed by 3392
Abstract
Background and Objectives: JAK inhibitors entered current clinical practice as treatment for several immune-related diseases and, recently, for atopic dermatitis. These drugs target the Janus Kinase intracellular cascade, rendering them suitable for treating both Th1 and Th2 immune-mediated responses. Materials and Methods [...] Read more.
Background and Objectives: JAK inhibitors entered current clinical practice as treatment for several immune-related diseases and, recently, for atopic dermatitis. These drugs target the Janus Kinase intracellular cascade, rendering them suitable for treating both Th1 and Th2 immune-mediated responses. Materials and Methods: We report the case of a 36-year-old male patient presenting an overlap of ulcerative colitis, a Th1-related disease, and atopic dermatitis, a Th2-mediated condition. Treatment with upadacitinib was initiated, and laboratory and instrumental follow-ups were carried out for 8 months. Results: The complete and persistent clinical remission of both conditions was observed at a low dose of 15 mg of upadacitinib, even though ulcerative colitis guidelines usually recommend a dosage of 45 mg. No serious adverse responses to therapy were reported. Conclusions: Upadacitinib may be the most suitable management strategy in subjects with coexisting severe conditions mediated by Th1 inflammation, such as ulcerative colitis, and by Th2 cytokines, such as atopic dermatitis. Full article
(This article belongs to the Special Issue Immune-Mediated Skin Diseases: Future Therapeutic Perspectives)
►▼ Show Figures

Figure 1

10 pages, 1056 KiB  
Case Report
Spontaneous Reversal of Vitiligo, a Rare Phenomenon Reported in a Case in Saudi Arabia with an Insight into Metabolic Biochemical Derangements
by Ayoub Ali Alshaikh and Rishi Kumar Bharti
Medicina 2023, 59(3), 427; https://doi.org/10.3390/medicina59030427 - 22 Feb 2023
Cited by 2 | Viewed by 7125
Abstract
Background and Objectives: Vitiligo is a skin disorder characterized by hypopigmented macules occurring due to melanocyte destruction. An interplay of several biochemical mechanisms has been proposed to explain the etiopathogenesis of vitiligo, such as genetic, autoimmune responses, generation of inflammatory mediators, oxidative stress, [...] Read more.
Background and Objectives: Vitiligo is a skin disorder characterized by hypopigmented macules occurring due to melanocyte destruction. An interplay of several biochemical mechanisms has been proposed to explain the etiopathogenesis of vitiligo, such as genetic, autoimmune responses, generation of inflammatory mediators, oxidative stress, and melanocyte detachment mechanisms. There is no cure for vitiligo; however, pharmacological treatment measures (cosmetic camouflage creams, steroids, psoralen and ultraviolet A (PUVA) therapy, narrowband UVB) are available, but they could have certain side effects. We reported an interesting case of vitiligo in Saudi Arabia that showed reversal of vitiligo, which is an extremely rare phenomenon, with the objective of probing the probable reasons for this reversal. To the best of our knowledge, there is no study on vitiligo that has reported spontaneous reversal of vitiligo in Saudi Arabia so far. Materials and Method: The patient presented to the Family Medicine clinic with a history of restoration of melanin pigment in his lesions after 3 years of the onset of vitiligo. Patients history was taken carefully along with clinical examination, carried out necessary biomedical lab investigations and compiled the data. The data at the time of pigment restoration were compared to the previous data when he developed the lesions. Result: The probable reasons for vitiligo reversal could be markedly decreased psychological stress, regular consumption of an antioxidant-rich herbal drink made of curcumin and honey, and dietary switchover to vegetarianism and an alcohol-free lifestyle. Conclusions: Curcumin-based herbal remedies could be an alternative option to treat vitiligo. These methods must be further explored through clinical trials as they are safer, easily available, and more affordable. Full article
(This article belongs to the Special Issue Immune-Mediated Skin Diseases: Future Therapeutic Perspectives)
►▼ Show Figures

Figure 1

19 pages, 721 KiB  
Systematic Review
Impact of Innovative Treatment Using Biological Drugs for the Modulation of Diffuse Cutaneous Systemic Sclerosis: A Systematic Review
by Diego Fernández-Lázaro, María Iglesias-Lázaro, Evelina Garrosa, Saray Rodríguez-García, David Jerves Donoso, Eduardo Gutiérrez-Abejón and Conrado Jorge-Finnigan
Medicina 2023, 59(2), 247; https://doi.org/10.3390/medicina59020247 - 27 Jan 2023
Cited by 4 | Viewed by 2621
Abstract
Scleroderma or systemic sclerosis (SSc) is an autoimmune disease affecting the connective tissue, characterized by fibrosis of the skin and internal organs. There is currently no curative treatment available, so therapeutic action is aimed at a symptomatic treatment of the affected organs. The [...] Read more.
Scleroderma or systemic sclerosis (SSc) is an autoimmune disease affecting the connective tissue, characterized by fibrosis of the skin and internal organs. There is currently no curative treatment available, so therapeutic action is aimed at a symptomatic treatment of the affected organs. The development of biotechnology has made it possible to implement certain biological drugs that could represent a window of opportunity to modulate the evolution and symptomatology of scleroderma with greater efficacy and less toxicity than conventional treatments. This study aimed to review the current evidence critically and systematically on the effects of biological drugs on the pulmonary function, skin disease, and health status of patients afflicted by diffuse cutaneous systemic sclerosis (dcSSc). Three electronic databases (Pubmed, Dialnet, and Cochrane Library Plus) were systematically searched until the cut-off date of October 2022. The review was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and included original articles in English and Spanish with a controlled trial design, comparing biological drug treatments (tocilizumab, belimumab, riociguat, abatacept, and romilkimab) with a control group. The methodological quality of the studies was assessed using the McMaster quantitative form and the PEDro scale. A total of 383 studies were identified, 6 of them met the established criteria and were included in the present systematic review. A total of 426 patients treated with tocilizumab, belimumab, riociguat, abatacept, and romilkimab were included. The results showed substantial non-significant (p < 0.05) improvement trends after treatment with the biological drugs included in this review for the modified Rodnan Scale Value, Forced Vital Capacity, and Carbon Monoxide Diffusion Test; however, no benefits were shown on the Health Assessment Questionnaire–Disability Index when compared to the control group. Biological drugs, therefore, maybe a new therapeutic strategy for dcSSc and could be recommended as an additional and/or adjunctive treatment that promotes anti-fibrotic activity. This review could further define the clinical rationale for the use of biologics in the treatment of dcSSc and could provide key details on the study protocol, design, and outcome reporting. Full article
(This article belongs to the Special Issue Immune-Mediated Skin Diseases: Future Therapeutic Perspectives)
►▼ Show Figures

Figure 1

7 pages, 300 KiB  
Opinion
Granulocyte Apheresis: Can It Be Associated with Anti PD-1 Therapy for Melanoma?
by Alvise Sernicola, Anna Colpo, Anca Irina Leahu and Mauro Alaibac
Medicina 2022, 58(10), 1398; https://doi.org/10.3390/medicina58101398 - 6 Oct 2022
Cited by 2 | Viewed by 2051
Abstract
In the field of advanced melanoma, there is an urgent need to investigate novel approaches targeting specific components of the cancer–immunity cycle beyond immune checkpoint inhibitors. The authors reviewed the basic understanding of the role of neutrophils in cancer biology, and the latest [...] Read more.
In the field of advanced melanoma, there is an urgent need to investigate novel approaches targeting specific components of the cancer–immunity cycle beyond immune checkpoint inhibitors. The authors reviewed the basic understanding of the role of neutrophils in cancer biology, and the latest clinical evidence supporting the correlation between cancer-associated neutrophils and the prognosis and response to the immunotherapy of advanced melanoma. Finally, they propose that granulocyte and monocyte apheresis, an emerging non-pharmacological treatment in current dermatology, could become an investigative treatment targeting melanoma-associated neutrophils which could be potentially used in combination with the usual immune checkpoint inhibitors. Full article
(This article belongs to the Special Issue Immune-Mediated Skin Diseases: Future Therapeutic Perspectives)
7 pages, 2917 KiB  
Case Report
Aseptic Abscess Syndrome in Rheumatoid Arthritis Patient
by Agnieszka Owczarczyk-Saczonek, Marta Kasprowicz-Furmańczyk, Jakub Kuna, Paulina Klimek and Magdalena Krajewska-Włodarczyk
Medicina 2022, 58(10), 1354; https://doi.org/10.3390/medicina58101354 - 27 Sep 2022
Cited by 6 | Viewed by 5960
Abstract
Aseptic abscess syndrome (AAS) is a rare, potentially life-threatening disorder, with numerous features of neutrophilic dermatoses. The main symptoms include aseptic abscess-like collections in internal organs (spleen, liver, lungs), lack of microbes (bacteria, viruses, or parasites) after an exhaustive search, ineffectiveness of antibiotics, [...] Read more.
Aseptic abscess syndrome (AAS) is a rare, potentially life-threatening disorder, with numerous features of neutrophilic dermatoses. The main symptoms include aseptic abscess-like collections in internal organs (spleen, liver, lungs), lack of microbes (bacteria, viruses, or parasites) after an exhaustive search, ineffectiveness of antibiotics, and high sensitivity to corticosteroid therapy. AAS is characterized by the development of deep, inflammatory abscesses and systemic symptoms (weight loss, abdominal pain, fever, and leukocytosis). They may be associated with inflammatory bowel disease (IBD) and autoimmune diseases. The patient in this study is a 67-year-old man, suffering from rheumatoid arthritis (RA), with numerous purulent abscesses in the mediastinum, within the subcutaneous tissue above the extension surfaces of the joints, and on the dorsum of the hands. The lesions are accompanied by bone destruction. The patient was treated with prednisone 40 mg and adalimumab, which resulted in a quick reduction of inflammatory markers and clinical improvement, as well as the healing and absorption of abscesses. Despite COVID-19 infection, treatment with remdesivir, prednisone, and adalimumab was continued, with the complete resolution of the lesions. AAS is difficult to recognize, so practitioners have to be aware of this condition, especially in patients with RA. Full article
(This article belongs to the Special Issue Immune-Mediated Skin Diseases: Future Therapeutic Perspectives)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-7
Back to TopTop